Monoterpene indole alkaloid azine derivatives as MDR reversal agents |
| |
Authors: | Angela Paterna Ruttiros Khonkarn Silva Mulhovo Alexis Moreno Patricia Madeira Girio Hélène Baubichon-Cortay Pierre Falson Maria-José U. Ferreira |
| |
Affiliation: | 1. Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal;2. Drug Resistance & Membrane Proteins Team, Molecular Microbiology & Structural Biochemistry Laboratory, Centre National de la Recherche Scientifique (CNRS) and Claude Bernard University Lyon 1 Joint Research Unit 5086, Institut of Biology and Chemistry of Proteins (IBCP), 7, passage du Vercors, 69367 Lyon, France;3. Centro de Estudos Moçambicanos e de Etnociências (CEMEC), Faculty of Natural Sciences and Mathematics, Pedagogical University, 21402161 Maputo, Mozambique |
| |
Abstract: | Aiming at generating a library of bioactive indole alkaloid derivatives as multidrug resistance (MDR) reversers, two epimeric indole alkaloids (1 and 2) were submitted to chemical transformations, giving rise to twenty-four derivatives (5-28), bearing new aromatic or aliphatic azine moieties. The structure of the compounds was established by 1D and 2D NMR (COSY, HMBC, HMQC and NOESY) experiments. Two different strategies were employed for assessing their anti-MDR potential, namely through the evaluation of their activity as inhibitors of typical MDR ABC transporters overexpressed by cell transfection, such as ABCB1 (P-gp), ABCC1 (MRP1), and ABCG2 (BCRP), or by evaluating their ability as collateral sensitivity (CS) agents in cells overexpressing MRP1. A considerable MDR reversing activity was observed for compounds bearing the aromatic azine moiety. The strongest and most selective P-gp inhibition was found for the epimeric azines 5 and 6, bearing a para-methylbenzylidene moiety. Instead, compounds 17 and 18 that possess a di-substituted benzylidene portion with methoxy and hydroxyl groups, selectively inhibited MRP1 drug-efflux. None of these compounds inhibited BCRP. Compounds 5, 6 and 18 were further investigated in drug combination experiments, which corroborated their anti-MDR potential. Moreover, it was observed that compound 12, with an aromatic azine moiety, and compounds 23-26, sharing a new aliphatic substituent, displayed a CS activity, selectively killing MRP1-overexpressing cells. Among these last compounds, it could be established that addition of 19, 23 and 25 to MRP1-overexpressing cells led to glutathione depletion triggering cell death through apoptosis. |
| |
Keywords: | ABC ATP binding cassette ABCB1 ATP binding cassette subfamily B member 1 ABCG2 ATP binding cassette subfamily G member 2 BCRP breast cancer resistance protein BHK-21 baby hamster kidney CS collateral sensitivity FACS fluorescence-activated cell sorting FBS fetal bovine serum DMEM Dulbecco’s Modified Eagle Medium GSH glutathione GSSG glutathione disulfide MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide PAR parental RR relative resistance ratio SD standard deviation Monoterpene indole alkaloids Multidrug resistance ABC drug transporters P-gp MRP1 BCRP Collateral sensitivity |
本文献已被 ScienceDirect 等数据库收录! |
|